The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: A meta-analysis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wang, Lei ^a   Wang, Rui ^a   Pan, Yunjian ^a   Sun, Yihua ^a   Zhang, Jie ^a   Chen, Haiquan ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Lung cancer; Meta analysis; Pemetrexed; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; GEMCITABINE; PEMETREXED; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CHEMOTHERAPY; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899121061     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-205     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002, 20(5):1335-1343. 10.1200/JCO.20.5.1335, 11870177.
3. Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Yun YH, Lee JW, Park K. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25(33):5233-5239. 10.1200/JCO.2007.10.8134, 18024869.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98. 10.1056/NEJMoa011954, 11784875.
5. Chen LK, Liang Y, Yang QY, Xu F, Zhou NN, Xu GC, Liu GZ. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev 2012, 13(5):1863-1867. 10.7314/APJCP.2012.13.5.1863, 22901137.
6. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3(10):1112-1118. 10.1097/JTO.0b013e3181874936, 2639211, 18827606.
7. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22(2):330-353.
8. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22(9):1589-1597. 10.1200/JCO.2004.08.163, 15117980.
9. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
10. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440. 10.1016/S0140-6736(09)61497-5, 19767093.
11. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999, 26(2 Suppl 6):42-47.
12. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003, 3(2):145-156. 10.1586/14737140.3.2.145, 12722874.
13. Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT, Ko JL. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 2010, 5(8):1143-1151. 10.1097/JTO.0b013e3181e0b954, 20559153.
14. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Wu CH, Sheu GT, Hsu SL. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Mol Carcinog 2011, doi:10.1002/mc.2184.
15. Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010, 101(1):161-166. 10.1111/j.1349-7006.2009.01358.x, 19811498.
16. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009, 66(2):141-149. 10.1016/j.lungcan.2009.06.006, 19577816.
17. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011, 6(8):1392-1399. 10.1097/JTO.0b013e3182208ea8, 21716147.
18. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011, 104(10):1594-1601. 10.1038/bjc.2011.129, 3101907, 21487406.
19. Wang ZK, Hu Y, Zhao H, Fu C. Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30(5):978-980.
20. Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res 2010, 30(10):4309-4315.
21. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011, 74(1):132-138. 10.1016/j.lungcan.2011.01.024, 21367480.
22. Park CK, Kim KS, Oh IJ, Tseden IM, Choi YD, Kwon YS, Kim YI, Lim SC, Kim YC. Efficacy of pemetrexed in relapsed non-small cell lung cancer and thymidylate synthase expression. Tuberc Respir Dis 2009, 67(3):191-198.
23. Nakagawa T, Tanaka F, Otake Y, Yanagihara K, Miyahara R, Matsuoka K, Takata T, Yamada T, Fukushima M, Wada H. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002, 35(2):165-170. 10.1016/S0169-5002(01)00407-X, 11804689.
24. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356(8):800-808. 10.1056/NEJMoa065411, 17314339.
25. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008, 300(14):1674-1684. 10.1001/jama.300.14.1674, 18840841.
26. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100(9):1385-1392. 10.1038/sj.bjc.6605017, 2694418, 19401698.
27. Check ML, Check JH, Choel JK, Davies E, Kiefer D. Effect of antagonists vs agonists on in vitro fertilization outcome. Clin Exp Obstet Gynecol 2004, 31(4):257-259.
28. Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69(3):323-329. 10.1016/j.lungcan.2009.12.002, 20061047.
29. Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y, Masuda N. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy 2012, 58(4):313-320. 10.1159/000343048, 23147191.
30. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010, 25(9):603-605. 10.1007/s10654-010-9491-z, 20652370.
31. Kyrgiou M, Tsoumpou I, Vrekoussis T, Martin-Hirsch P, Arbyn M, Prendiville W, Mitrou S, Koliopoulos G, Dalkalitsis N, Stamatopoulos P, Paraskevaidis E. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 2006, 32(7):516-523. 10.1016/j.ctrv.2006.07.008, 17008015.
32. Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol 2010, 5(4):484-490. 10.1097/JTO.0b013e3181ccb27b, 2861290, 20107425.
33. Makimoto T, Tsuchiya S, Nakano H, Watanabe S, Minato K, Takise A, Ezawa K, Fueki N, Naruse I, Nomoto T, Takei Y, Ishihara S, Mori M, Saitoh R. A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer. Am J Clin Oncol 1997, 20(1):51-54. 10.1097/00000421-199702000-00011, 9020288.
34. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz R. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57(6):1116-1123.
35. Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, Oda M, Sasaki T, Watanabe G. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep 2006, 15(6):1533-1539.
36. Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Tagawa M, Tatsumi K. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines. Oncol Rep 2012, 28(1):33-40.
37. Ibe T, Shimizu K, Nakano T, Kakegawa S, Kamiyoshihara M, Nakajima T, Kaira K, Takeyoshi I. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. J Surg Oncol 2010, 102(1):11-17. 10.1002/jso.21576, 20578072.
38. Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S, Papotti M. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009, 15(24):7547-7552. 10.1158/1078-0432.CCR-09-1641, 19996214.
39. Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol 2012, 7(1):105-114. 10.1097/JTO.0b013e3182352a45, 22134068.
40. Nazki FH, Masood A, Banday MA, Bhat A, Ganai BA. Thymidylate synthase enhancer region polymorphism not related to susceptibility to acute lymphoblastic leukemia in the Kashmir population. Genet Mol Res 2012, 11(2):906-917. 10.4238/2012.April.10.6, 22576918.
41. Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010, 28(9):1534-1539. 10.1200/JCO.2009.25.9275, 20177021.
42. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 55(7):1407-1412.
43. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998, 82(1):70-77. 10.1002/(SICI)1097-0142(19980101)82:1<70::AID-CNCR8>3.0.CO;2-O, 9428481.
44. Karlberg M, Ohrling K, Edler D, Hallstrom M, Ullen H, Ragnhammar P. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res 2010, 30(2):645-651.
45. Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR, Zheng MH. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008, 123(10):2384-2389. 10.1002/ijc.23822, 18729195.
46. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, Maeda H, Kido T, Miyoshi S, Matsuda H. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003, 104(6):790-795. 10.1002/ijc.11014, 12640689.
47. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.